在财报电话会议上,首席执行官杜莹博士强调公司收入同比增长47%至1.018亿美元,并指出公司在管线方面取得了战略性进展,包括前景看好的DLL3靶向ADC药物ZL-1310。再鼓实验室有望在2025年底前实现盈利,目前现金储备为7.16亿美元。

Zai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administrat ...

First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – ...

(ARGX) and Zai Lab Limited (ZLAB) announced that China’s National Medical Products Administration, NMPA, approved the supplemental ...

Just a few months into a new launch in chronic inflammatory demyelinating polyneuropathy (CIDP), agrenx’ Vyvgart is already making headway in the rare disease space, just one of the long-term growt | ...

Zai Lab Limited (NASDAQ: ZLAB) and argenx (NASDAQ: ARGX) today announced that China’s National Medical Products Administration (NMPA) approved the supplemental Biologics License Application (sBLA) for ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2024, along with recent product highlights and corporate ...

The launch of VYVGART Hytrulo for chronic inflammatory demyelinating polyneuropathy (CIDP) has further expanded the product's reach, with over 300 CIDP patients already receiving treatment.

Based on this expansion, argenx has now exclusively licensed ENHANZE for a total of six targets, including VYVGART Hytrulo. As part of the agreement, argenx will make a $30 million payment to ...

The drug has shown strong uptake in the gMG market, with over 10,000 patients currently being treated. The launch of VYVGART Hytrulo for chronic inflammatory demyelinating polyneuropathy (CIDP) has ...